Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:02:29.745Z.
Calculation as of: 2026-10-06T16:02:29.745Z.
Quote observation: 2026-10-06T15:58:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b5b90a83151b8a074e07f32cd5a8423240b7dae761ecc8f52934664174c7f924
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$35.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$34.55M
EV/EBITDA Ratio
N/A
TTM Avg
25.79x
3Y Avg
51.85x
5Y Avg
38.84x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elutia Inc (ELUT) | $35.42M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.62M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | N/A | 6.76x | 19.14x | 45.56x |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.58M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $34.55M | N/A | 25.79x | 51.85x | 38.84x |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.23M | N/A | N/A | N/A | N/A |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.63M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.93M | N/A | N/A | N/A | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $36.99M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.76M | N/A | 10986.66x | 10986.66x | 10986.66x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
